Eric P. Lester - Concepedia

Author

Eric P. Lester

Also Known As

E Lester, E P Lester, E. Lester, E. P. LESTER, E. P. Lester, E.P. LESTER, E.P. Lester, ERIC P. LESTER, Eric Lester, Eric P Lester

Publications

2.3K

Citations

H-Index

123

Concepts

All Affiliations

University of Chicago National Cancer Institute Franklin Institute NorthShore University HealthSystem The University of Texas MD Anderson Cancer Center

About

Eric P. Lester is an author at University of Chicago specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.4K
2	Health Sciences	10	10	408
3	Natural Sciences	5	5	386
4	Engineering	3	3	115
5	Public Health	1	1	18

Eric P. Lester

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Polyamines as physiological substrates for transglutaminases. J.E. Folk, M.H. Park, Soo Il Chung, Journal of Biological Chemistry Such Cross-linkingGlycobiologyPhysiological SubstratesReproductive BiologyExperimental Pharmacology	1980	311
Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium Sonali M. Smith, Koen van Besien, Theodore Karrison, Journal of Clinical Oncology	2010	207
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. C. Patrick Burns, Susan Halabi, Gerald H. Clamon, PubMed Lipid AnalysisOncologyCancer CachexiaChemoprevention StrategyOmega-3 Fatty Acid	1999	110
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. Thomas Beck, Paul J. Hesketh, Stefan Madajewicz, Journal of Clinical Oncology	1992	101
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. Paul J. Hesketh, William K. Murphy, Eric P. Lester, Journal of Clinical Oncology Drug SafetyMedicinePharmacologyClinical TrialsNovel Compound	1989	101
Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762) Stuart M. Lichtman, Donna Hollis, Antonius A. Miller, Journal of Clinical Oncology	2006	91
Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer Ezra E.W. Cohen, Daniel J. Haraf, Rangesh Kunnavakkam, Journal of Clinical Oncology	2010	85
Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer Caio Max S. Rocha Lima, Diane Savarese, Howard W. Bruckner, Journal of Clinical Oncology UrologyPancreatic CancerPhase IiGastrointestinal OncologyMedicine	2002	73
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer Nicholas W. Choong, Ann M. Mauer, Daniel J. Haraf, Journal of Thoracic Oncology MedicineErlotinib-based Multimodality TherapyPharmacologyMultimodalityCombined Modality Treatment	2008	69
Human alpha-fetoprotein as a modulator of human lymphocyte transformation: correlation of biological potency with electrophoretic variants. Eric P. Lester, John B. Miller, Stanley Yachnin Proceedings of the National Academy of Sciences ImmunologyGenetic EpidemiologyPathologyBlood CellBioanalysis	1976	67

Page 1